| Literature DB >> 33771203 |
Ming Liu1,2, Ya Gao1,2, Yuan Yuan3, Shuzhen Shi1,2, Kelu Yang1,4, Jiyuan Shi1,4, Jiarui Wu5, Junhua Zhang6, Jinhui Tian7,8.
Abstract
BACKGROUND: Sjogren's syndrome (SS) is a chronic autoimmune rheumatic disease with an incidence of 0.03 to 0.3%. In recent years, there are an increasing number of randomized controlled trials of traditional Chinese medicine (TCM) for SS. However, there are generally some problems in these published clinical trials: lack of reporting primary or long-term outcomes and the heterogeneous in different clinical trials' outcome. Our study aims to determine the priority outcomes and standard TCM syndromes for all stakeholders and reach agreement on the COS and syndromes to be measured and reported in all future TCM trials in patients with SS. METHODS AND ANALYSIS: A phase-wise refinement approach will be used, consisting of three phases, yet complementary, sub-work phases, whereby each phase will inform the next coming phases. The following are the three phases: (I-a) identifying of a long initial list of outcomes through systematic literature review and semi-structured qualitative interviews and (I-b) identifying an initial list of TCM syndromes through (1) systematic literature review, (2) referencing ancient Chinese medical books, and (3) retrospective studies of medical records; (II) prioritization of outcomes using Delphi survey with different stakeholders, such as health professionals and patients; and (III) through consensus meetings with patients and professionals to agree on the final COS and TCM syndromes. DISCUSSION: We summarized the actions of COS into three points: direct action, indirect action, and final action. After the final COSs is completed, we will publish this research in a journal to promote communication. TRIAL REGISTRATION: Core Outcome Measures in Effectiveness Trials Initiative (COMET) number 1429 . Registered on 01 December 2019.Entities:
Keywords: Core set comes; Protocol; Sjogren’s syndrome; Traditional Chinese medicine
Mesh:
Year: 2021 PMID: 33771203 PMCID: PMC7999517 DOI: 10.1186/s13063-021-05187-8
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.728